Fig. 1: Identification and clinical relevance of chimeric RNA CCDC7_19-13 in prostate cancer.

A Workflow for identifying chimeric RNAs in the CPGEA prostate cancer dataset. Starting from 101,973 initial reads, 2936 EE fusions were identified. Filtering for recurrent events (≥5 times) yielded 487 candidates, further confirmed through UCSC (275 candidates), Eriscript (69 candidates, p < 0.05), and Agrep analysis (48 candidates, p < 0.05). B Top 20 chimeric RNAs by frequency in the CPGEA dataset, ranked by -log10(p-value). CCDC7_19-13 is highlighted for its significant differential expression and high frequency. C Comparison of CCDC7_19-13 expression levels in normal (n = 134) and tumor (n = 134) tissues using an unpaired t-test, showing significantly lower expression in tumor tissues. D Paired t-test comparison of CCDC7_19-13 expression in matched normal and tumor tissues (n = 134), showing significantly reduced expression in tumor tissues. E Violin plot of CCDC7_19-13 expression stratified by Gleason score (GS): GS ≤ 7 (n = 10) and GS > 7 (n = 63). F Violin plot comparing CCDC7_19-13 expression in non-biochemically recurrent (Non-BCR, n = 85) and biochemically recurrent (BCR, n = 49) prostate cancer tissues, showing lower expression in BCR tissues. G Kaplan–Meier analysis of progression-free survival in prostate cancer patients with high versus low CCDC7_19-13 expression. Higher expression correlates with better prognosis (log-rank p = 0.0063, HR = 0.3512, CI: 0.3512–0.8394). H Kaplan–Meier analysis of overall survival in prostate cancer patients with high versus low CCDC7_19-13 expression, showing improved survival with higher expression (log-rank p = 0.0041, HR = 0.2114, CI: 0.2114–0.7096). I, J Expression of CCDC7_19-13 in different cohorts. I Cohort 1 stratified by normal adjacent tissue (NAT, n = 78), high-risk primary prostate cancer (HSPC, n = 36), castration-resistant prostate cancer (CRPC, n = 17), and metastatic CRPC (mCRPC, n = 14). J Cohort 2 stratified by NAT (n = 65), HSPC (n = 68), CRPC (n = 18), and mCRPC (n = 16). K Expression of CCDC7_19-13 in Cohort 3, comparing Non-BCR (n = 152) and BCR (n = 42) prostate cancer tissues. L–N Expression of CCDC7_19-13 stratified by Gleason score in different cohorts. L Cohort 1: GS ≤ 7 (n = 22) and GS > 7 (n = 32 and n = 24). M Cohort 2: GS ≤ 7 (n = 29) and GS > 7 (n = 40 and n = 33). N Cohort 3: GS ≤ 7 (n = 43) and GS > 7 (n = 80 and n = 71). The asterisks denote the level of statistical significance as follows: *p < 0.05, **p < 0.01, ***p < 0.001.